U.S. health regulators approved ImmunityBio’s combination therapy for a type of bladder cancer on Monday, ending the company’s efforts to bring its treatment to market. The agency’s green light is a shot in the arm for ImmunityBio, which reiterated doubts in regulatory filings last month about its ability to stay in business.